Gennex Laboratories Q1 FY27 Net Profit at ₹3.96 Crore

Board Meeting Details

The Board Meeting commenced at 4:00 PM and concluded at 4:40 PM on August 14, 2026. The Board approved and considered the following items:

Unaudited (Standalone and Consolidated) Financial Statements for the Quarter ended June 30, 2026
Limited review reports from the Statutory Auditor on Unaudited (Standalone and Consolidated) Financial Statements for the Quarter ended June 30, 2026
Other Business items

Standalone Financial Results (Q1 FY27 ended June 30, 2026)

Income Statement (₹ in Lakhs)

Revenue from Operations: ₹3,467.79 (Q1 FY26: ₹2,564.00; Q4 FY26: ₹3,671.41)
Other Income: ₹199.70 (Q1 FY26: ₹226.44; Q4 FY26: ₹129.79)
Total Income: ₹3,667.49 (Q1 FY26: ₹2,790.44; Q4 FY26: ₹3,801.20)

Expenses Breakdown (₹ in Lakhs)

Cost of material consumed: ₹2,601.43
Changes in stock-in-trade and Work in Progress: ₹93.83
Employees Cost: ₹166.47
Depreciation: ₹23.92
Finance Cost: ₹50.88
Other Expenses: ₹310.43
Total Expenses: ₹3,246.96

Profitability Metrics

Total Profit before exceptional Items & Tax: ₹420.53
Exceptional items: None
Corporate Social Responsibility: None for the quarter (₹30.00 in Q4 FY26)
Total profit before tax: ₹420.53
Current tax: ₹25.00
Deferred Tax: None for the quarter (₹20.89 in Q4 FY26)
Total Tax Expenses: ₹25.00
Net profit: ₹395.53 (Q1 FY26: ₹414.95; Q4 FY26: ₹299.44)

Capital Structure and Per Share Data

Paid up equity share capital: ₹2,429.48 lakhs
Face value of equity share: ₹1.00
Basic EPS: ₹0.163 (Q1 FY26: ₹0.179; Q4 FY26: ₹0.125)
Diluted EPS: ₹0.163 (Q1 FY26: ₹0.171; Q4 FY26: ₹0.125)

Consolidated Financial Results (Q1 FY27 ended June 30, 2026)

Income Statement (₹ in Lakhs)

Revenue from Operations: ₹3,984.17 (Q1 FY26: ₹3,417.75; Q4 FY26: ₹6,095.50)
Other Income: ₹200.82 (Q1 FY26: ₹227.74; Q4 FY26: ₹131.87)
Total Income: ₹4,184.99 (Q1 FY26: ₹3,645.49; Q4 FY26: ₹6,227.37)

Expenses Breakdown (₹ in Lakhs)

Cost of material consumed: ₹2,967.25
Changes in stock-in-trade and Work in Progress: -₹3.54
Employees Cost: ₹197.57
Depreciation: ₹56.89
Finance Cost: ₹89.97
Other Expenses: ₹385.21
Total Expenses: ₹3,693.35

Profitability Metrics

Total Profit before exceptional Items & Tax: ₹491.64
Exceptional items: None
Corporate Social Responsibility: None for the quarter (₹30.00 in Q4 FY26)
Total profit before tax: ₹491.64
Current tax: ₹25.00
Deferred Tax: None for the quarter (₹20.89 in Q4 FY26)
Total Tax Expenses: ₹25.00
Net profit: ₹466.64 (Q1 FY26: ₹501.64; Q4 FY26: ₹445.86)
Comprehensive income for the period attributable to owners of parent: ₹431.79

Capital Structure and Per Share Data

Paid up equity share capital: ₹2,429.48 lakhs
Face value of equity share: ₹1.00
Basic EPS: ₹0.192 (Q1 FY26: ₹0.217; Q4 FY26: ₹0.156)
Diluted EPS: ₹0.192 (Q1 FY26: ₹0.206; Q4 FY26: ₹0.156)

Segment Reporting and Geographical Revenue

The company has one reportable segment: "Bulk Drugs, Biotech Products and Intermediates".

Country-wise Revenue Distribution (₹ in Lakhs)

Key markets for Q1 FY27:

India: ₹2,537.08 (73.2% of total revenue)
Colombia: ₹350.60
Egypt: ₹253.58
Vietnam: ₹81.72
Peru: ₹89.75
Guatemala City: ₹67.99
Mexico: ₹37.65
Ecuador: ₹28.83
Bolivia: ₹4.18
Russia: ₹10.00
Spain: ₹2.67
Zimbabwe: ₹3.74
Total Revenue: ₹3,467.79

Subsidiary Information

Consolidated figures include subsidiary Deccan Remedies Ltd with:

Sales (Net) to subsidiary: ₹271.93 lakhs
Purchase (Net) from subsidiary: ₹41.20 lakhs
The subsidiary contributed total revenues of ₹2,517.50 lakhs and net profit after tax of ₹71.11 lakhs for the quarter

Regulatory and Compliance Notes

The unaudited financial results were reviewed by the Audit Committee and approved by the Board on August 14, 2026
Statutory Auditors (R Pugalia & Company) carried out limited review of both standalone and consolidated results
Results prepared in accordance with Companies (Indian Accounting Standards) Rules, 2015 (IND-AS)
Adjustment of actuarial valuation for employee benefits (AS-19) to be done at year-end
Previous period's figures have been rearranged/regrouped where necessary
Results available on company website (www.gennexlab.com) and BSE website (www.bseindia.com)

Auditor's Limited Review

R Pugalia & Company issued limited review reports for both standalone and consolidated results, stating that nothing has come to their attention that causes them to believe the statements contain any material misstatement. The review was conducted in accordance with SRE 2410 issued by ICAI.